Results 91 to 100 of about 5,494 (193)
Psychiatry and Clinical Neurosciences, Volume 80, Issue 9, Page 740-747, September 2026.Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Aran Tajika +5 more
wiley +1 more source
Resultados terapéuticos del fármaco aducanumab en el tratamiento del Alzheimer [PDF]
, 2022 Introducción: La enfermedad del Alzheimer (EA) se trata de una patología que en los últimos años ha visto aumentada su incidencia. A pesar de esto, no existe ningún tratamiento eficaz para eliminar o reducir el declive clínico.
Gil Palao, Nuria
core +1 more source
Volume change with gantenerumab: Impact of amyloid‐related imaging abnormalities and amyloid removal
Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.Abstract INTRODUCTION Amyloid‐lowering antibodies are associated with neuroanatomical volume changes. This study aims to disentangle the contributions of amyloid‐related imaging abnormalities (ARIA) and amyloid clearance to these changes. METHODS Data from the GRADUATE I and II trials of gantenerumab in early Alzheimer's disease were analyzed ...
Matteo Tonietto +6 more
wiley +1 more source
Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies
eLifeA hallmark of Alzheimer’s disease (AD), the most common form of dementia, is the progressive accumulation of amyloid-beta (Aβ) peptides across distinct brain regions.
Ivan Talucci +14 more
doaj +1 more source
Beyond the Cochrane review: Re‐evaluating anti‐amyloid therapy in Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.Abstract The global burden of Alzheimer's disease (AD) is accelerating, with U.S. prevalence projected to reach nearly 13 million by 2060. Although the “amyloid cascade hypothesis” has long‐guided drug development, a 2026 Cochrane review challenged amyloid beta (Aβ) targets for therapy by citing insufficient clinical benefit and safety concerns.
Megan M. Bernath +5 more
wiley +1 more source
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data
, 2021 According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques - a hallmark finding in patients with Alzheimer's disease - and this will result in a reduction in clinical decline.
Alavi, Abass, Høilund-Carlsen, Poul F.
core +1 more source
, 2022 A sporadic Alzheimer’s blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau ...
LE Oikari (14868271) +13 more
core
Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve
BiomedicinesBackground: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled.
Sarfaraz K. Niazi
doaj +1 more source
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
Frontiers in PharmacologyBackgroundAlzheimer’s disease poses a major public health challenge, with aducanumab’s approval in 2021 as the first disease-modifying therapy raising important safety considerations.
Jingjing Huang +2 more
doaj +1 more source
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
, 2018 Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7 of the Aβ ...
Thierry Bussière +11 more
core +1 more source